Cipla Colombia SAS Y/O Deposito UPS Pharmaceutical Import Profile — Colombia (DGFT 2022–2026)

Name: Cipla Colombia SAS Y/O Deposito UPS Pharmaceutical Import Records from India — 4 Products, $2.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Cipla Colombia SAS Y/O Deposito UPS — Pharmaceutical Importer Profile (2026) | 4 Products, $2.4M Trade | TransData Nexus

Cipla Colombia SAS Y/O Deposito UPS

Pharmaceutical Importer · Colombia · Respiratory Focus · $2.4M Total Trade · DGFT Verified

Cipla Colombia SAS Y/O Deposito UPS is a pharmaceutical importer based in Colombia with a total trade value of $2.4M across 4 products in 3 therapeutic categories. Based on 77 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Cipla Colombia SAS Y/O Deposito UPS sources from 1 verified Indian supplier, with Cipla Limited accounting for 100.0% of imports.

Cipla Colombia SAS Y/O Deposito UPS — Import Portfolio & Supplier Network

Cipla Colombia SAS Y/O Deposito UPS import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Cipla Colombia SAS Y/O Deposito UPS?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Cipla Limited	$4.3M	366	100.0%

Cipla Colombia SAS Y/O Deposito UPS sources from 1 verified Indian supplier across 153 distinct formulations. The sourcing is highly concentrated — Cipla Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Cipla Colombia SAS Y/O Deposito UPS Import?

Formulation	Value	Ships
Salbumed 100 MCG hfa inhaler	$1.1M	36
Salbumed 100 MCG hfa inhaler (salbutamolsulphate 100 MCG)	$308.4K	8
Tenomune 300/200/600 tablets	$200.0K	4
Beclort 250mcg hfa inhaler (beclometasone dipropionate 250 MCG)	$167.7K	5
Lenoside 25MG capsules (lenalinomide 25MG) . (inv. qty. 1080 Pack 3 x7s=22680nos	$150.0K	3
Oncoemet 8 MG tablet (ondansetron 8 MG)	$138.7K	10
Salbumed 100 MCG hfa inhaler (salbutamolsulphate 100 MCG	$129.3K	9
Beclort 250mcg hfa inhaler	$113.3K	3
Salbumed 100mcg hfa inhaler (sulbutamolsulphate 100mcg) (1x200md)	$111.8K	3
Lenoside 25MG capsules (lenalinomide	$100.0K	2
Beclort 250 MCG hfa inhaler	$88.8K	2
Serohale ciphaler 50-250 (salmeterol	$82.3K	2
Beclort 250mcg hfa inhaler (beclometasone dipropionate 250 MCG	$82.0K	9
Zentair 0.5MG tablet (entecavir 0.5MG)	$75.9K	3
Tenomune 300/200/600 tablets (efavirenz600 MG, emtricitabine 200 MG and tenofovir disoproxil fumarate 300 MG)	$75.8K	2

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Salbutamol	Respiratory	$1.7M	60	1.2%	13
2	Efavirenz	Antivirals	$350.0K	7	0.6%	16
3	Tiotropium	Respiratory	$203.5K	7	0.3%	10
4	Lenalidomide	Advanced Oncology	$150.0K	3	0.0%	11

Cipla Colombia SAS Y/O Deposito UPS imports 4 pharmaceutical products across 3 categories into Colombia totaling $2.4M.

Cipla Colombia SAS Y/O Deposito UPS — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Cipla Colombia SAS Y/O Deposito UPS is a Colombian pharmaceutical importer and distributor headquartered in Bogotá D.C., Colombia. Established on April 25, 2019, the company operates as a Sociedad por Acciones Simplificada (SAS), a simplified joint-stock company structure commonly used in Colombia. Its primary activity is the wholesale distribution of pharmaceutical products, including medicinal drugs, cosmetics, and toiletries.

The company serves as a key player in Colombia's pharmaceutical supply chain, sourcing a diverse range of finished pharmaceutical formulations from international suppliers. This strategic approach enables Cipla Colombia SAS Y/O Deposito UPS to meet the growing demand for various therapeutic products within the Colombian market.

2Distribution Network

Cipla Colombia SAS Y/O Deposito UPS operates a centralized distribution model from its headquarters in Bogotá D.C., Colombia. While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic position in Bogotá suggests a focus on efficient distribution throughout Colombia. The capital city's infrastructure likely facilitates streamlined logistics, enabling the company to serve a broad geographic area within the country.

3Industry Role

In Colombia's pharmaceutical supply chain, Cipla Colombia SAS Y/O Deposito UPS functions primarily as a wholesaler and distributor. By importing finished pharmaceutical formulations from international suppliers, the company plays a crucial role in ensuring the availability of a wide array of medicinal products across the Colombian market. This position allows Cipla Colombia SAS Y/O Deposito UPS to bridge the gap between global pharmaceutical manufacturers and local healthcare providers, contributing to the overall accessibility of essential medicines in Colombia.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Cipla Colombia SAS Y/O Deposito UPS

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Cipla Colombia SAS Y/O Deposito UPS demonstrates a high degree of sourcing concentration, with 100% of its pharmaceutical imports originating from a single supplier: Cipla Limited of India. This exclusive sourcing strategy indicates a deep-rooted partnership, potentially offering benefits such as favorable pricing, consistent product quality, and reliable supply chain management. However, this single-source dependency also introduces risks, including vulnerability to supply disruptions, price fluctuations, and potential regulatory changes affecting the supplier. The stability of this relationship is crucial; any disruptions could significantly impact Cipla Colombia SAS Y/O Deposito UPS's ability to meet market demand.

2Supply Chain Resilience

The resilience of Cipla Colombia SAS Y/O Deposito UPS's supply chain is closely tied to its exclusive relationship with Cipla Limited. While this partnership may offer streamlined operations and consistent product quality, it also exposes the company to risks associated with single-source dependency. The absence of backup suppliers and limited formulation diversity could pose challenges in the event of supply chain disruptions. Additionally, reliance on a single supplier may limit the company's ability to adapt to changing market demands or regulatory requirements. Ensuring compliance with Colombian regulations and maintaining a robust logistics framework are essential to mitigate potential vulnerabilities in the supply chain.

Importing Pharmaceuticals into Colombia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Colombia

1Regulatory Authority & Framework

In Colombia, the primary regulatory authority overseeing pharmaceutical imports is the National Institute for Food and Drug Surveillance (INVIMA). INVIMA is responsible for ensuring the safety, efficacy, and quality of health-related products entering the Colombian market. The regulatory framework governing pharmaceutical imports includes Decree 677 of 1995, which outlines the sanitary registration requirements for drugs and biological products. This decree mandates that all pharmaceutical products imported into Colombia must obtain sanitary registration from INVIMA before they can be marketed and distributed within the country. (serviciolegal.com.co)

2Import Licensing & GMP

Importers in Colombia must adhere to specific licensing requirements to legally bring pharmaceutical products into the country. This includes obtaining a Tax Identification Number (NIT) and registering with the Single Tax Registry (RUT) through the National Tax and Customs Directorate (DIAN). Additionally, importers are required to register with the Single Window for Foreign Trade (VUCE) platform. For health-related products, prior approval from INVIMA is mandatory, and importers must secure permits from relevant government agencies before the cargo departs from the country of origin.

Quality & Labeling

Cipla Colombia SAS Y/O Deposito UPS — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Cipla Colombia SAS Y/O Deposito UPS's product strategy focuses on importing pharmaceutical formulations across three therapeutic categories: Respiratory (79.6%), Antivirals (14.3%), and Advanced Oncology (6.1%). This strategic focus aligns with the significant demand for respiratory medications, particularly in the context of chronic respiratory diseases prevalent in Colombia. The inclusion of antiviral and oncology products addresses critical healthcare needs, reflecting the company's commitment to providing comprehensive therapeutic solutions. The substantial import value of Salbutamol, a key respiratory medication, underscores the market's demand for such treatments.

2Sourcing Profile

Cipla Colombia SAS Y/O Deposito UPS's sourcing strategy is heavily centered on generic drug formulations, with a particular emphasis on respiratory medications. The exclusive partnership with Cipla Limited, an Indian multinational pharmaceutical company, facilitates access to a diverse range of high-quality generic products. This collaboration enables the company to offer cost-effective therapeutic options to the Colombian market, catering to the needs of both public and private healthcare sectors.

3Market Positioning

Seller's Guide — How to Become a Supplier to Cipla Colombia SAS Y/O Deposito UPS

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Cipla Colombia SAS Y/O Deposito UPS. The company's exclusive sourcing from Cipla Limited indicates a potential openness to diversifying its supplier base. Indian exporters can explore this opportunity by offering complementary products, ensuring competitive pricing, and demonstrating reliability in supply chain operations. Additionally, understanding the regulatory requirements and quality standards specific to the Colombian market will be crucial for establishing successful partnerships.

2Requirements & Qualifications

Indian exporters aiming to supply Cipla Colombia SAS Y/O Deposito UPS and the broader Colombian market must ensure compliance with INVIMA's regulatory standards. This includes obtaining sanitary registration for pharmaceutical products, adhering to Good Manufacturing Practice (GMP) certifications recognized by INVIMA, and ensuring that products meet Colombian labeling and packaging requirements. Additionally, exporters must navigate Colombia's import licensing procedures, including registration with DIAN and the VUCE platform, to facilitate smooth market entry.

How to Approach

Frequently Asked Questions — Cipla Colombia SAS Y/O Deposito UPS

What products does Cipla Colombia SAS Y/O Deposito UPS import from India?

Cipla Colombia SAS Y/O Deposito UPS imports 4 pharmaceutical products across 3 categories. Top imports: Salbutamol ($1.7M), Efavirenz ($350.0K), Tiotropium ($203.5K), Lenalidomide ($150.0K).

Who supplies pharmaceuticals to Cipla Colombia SAS Y/O Deposito UPS from India?

Cipla Colombia SAS Y/O Deposito UPS sources from 1 verified Indian suppliers. The primary supplier is Cipla Limited (100.0% of imports, $4.3M).

What is Cipla Colombia SAS Y/O Deposito UPS's total pharmaceutical import value?

Cipla Colombia SAS Y/O Deposito UPS's total pharmaceutical import value from India is $2.4M, based on 77 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Cipla Colombia SAS Y/O Deposito UPS focus on?

Cipla Colombia SAS Y/O Deposito UPS imports across 3 categories. The largest: Respiratory (79.6%), Antivirals (14.3%), Advanced Oncology (6.1%).

Get Full Cipla Colombia SAS Y/O Deposito UPS Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.